This report provides a synthesis of findings from the evidence based on the critical appraisal of systematic reviews and grey literature reports (NHSScotland)
Bibliography: Interventions – Harm Reduction
Understanding the pathway: barriers to data collection and onward referral to specialist hepatitis C services for PWID in London (PDF)
These recommendations reflect those made by the LJWG in its publication Commissioning of hepatitis C (HCV) services in London for People Who Inject Drugs report from 2013 suggesting that there is still significant action and progress needed to increase access to HCV treatment.
The Evaluation of the Drug Recovery Wing Pilots (PDF)
In 2012, the Department of Health commissioned an evaluation of these pilots, which has been undertaken by researchers at the University of York, the Centre for Drug Use Research in Glasgow and the University of Cambridge
The opioid crisis in north America (PDF)
To mitigate the current crisis, the Global Commission on Drug Policy recommends:
The case for a national prescribed drug helpline (PDF)
All Party Parliamentary Group for Prescribed Drug Dependence
Psychoactive substances in secure mental health settings
This review summarises the latest evidence and makes recommendations for secure mental health service commissioners and providers (Public Health England)
A model drug law to 2020 and beyond
The key to moving towards an Aotearoa free from drug harm is to start treating drug use as a health issue rather than a criminal issue. Download (New Zealand Drug Foundation)
Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017 (PDF)
The Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017 (the Bill) seeks to amend the Drugs, Poisons and Controlled Substances Act 1981 (the Principal Act), to provide for the licencing and operation of a medically supervised injecting centre (MSIC) for a trial period of 18 months (Parliament of Victoria, Australia)
Still no harm reduction? (PDF)
A critical review of the UK Government’s new Drug Strategy (drugscience)
Widening the availability of naloxone
Updated 1 August 2017 (DoH)
Improving clinical responses to drug-related deaths (PDF)
A summary of best practice and innovations from drug treatment providers (NHS Substance Misuse Provider Alliance)
Hepatitis C Screening (PDF)
National Clinical Guideline (Irish Government)
3.1.4 People who use unprescribed or illicit drugs
3.1.5 Prisoners
3.1.6 People who are homeless
Preventing drug related deaths (PDF)
Drug-related deaths are rising and are a major concern to councils and our health partners. Deaths have increased sharply over the past five years and are now at their highest levels since records began. The reasons for the jump are varied. When Public Health England (PHE) and the Local Government Association (LGA) investigated it last year they came to a number of conclusions
Interim report prepared by White House Commission on Combating Drug Addiction and the Opioid Crisis
Recommendations for action (White House)
Take-home naloxone for opioid overdose in people who use drugs
Advice for local authorities and local partners on widening the availability of naloxone to reduce overdose deaths from heroin and other opiate drugs (Public Health England)
Widening the availability of naloxone
Naloxone is a prescription-only medicine and cannot therefore be sold over the counter. It can however be supplied without prescription by drug services. It can be used by anyone to save a life in an emergency (DoH)
Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States (National Academy of Sciences.)
Hepatitis C in England and the UK
Latest hepatitis C virus (HCV) reports, slide sets and infographics for England and the UK (Public Health England)
Reducing Harm, Supporting Recovery 2017 – 2025
Ireland’s “Reducing Harm, Supporting Recovery” strategy sets out the Government’s response to addressing the harm caused by substance misuse in our society over the next eight years. It identifies a set of key actions to be delivered between 2017 and 2020, and provides an opportunity for the development of further actions from 2021 to 2024 to address needs that may emerge later on in the lifetime of the strategy (DoH, Ireland)
2017 Drug Strategy (PDF)
This Strategy sets out clear expectations for action from a wide range of partners, including those in education, health, safeguarding, criminal justice, housing and employment (Home Office)
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 24
- Next Page »